282 related articles for article (PubMed ID: 25755752)
21. Prognostic factors in surgical resection of sacral chordoma.
Angelini A; Pala E; Calabrò T; Maraldi M; Ruggieri P
J Surg Oncol; 2015 Sep; 112(4):344-51. PubMed ID: 26238085
[TBL] [Abstract][Full Text] [Related]
22. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients.
Hsieh PC; Xu R; Sciubba DM; McGirt MJ; Nelson C; Witham TF; Wolinksy JP; Gokaslan ZL
Spine (Phila Pa 1976); 2009 Sep; 34(20):2233-9. PubMed ID: 19752710
[TBL] [Abstract][Full Text] [Related]
23. Changes in tumor volume of sacral chordoma after carbon ion radiotherapy.
Serizawa I; Imai R; Kamada T; Tsuji H; Kishimoto R; Kandatsu S; Tsujii H; Tatezaki S
J Comput Assist Tomogr; 2009; 33(5):795-8. PubMed ID: 19820514
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the Infiltrative Features of Chordoma: The Relationship Between Micro-Skip Metastasis and Postoperative Outcomes.
Akiyama T; Ogura K; Gokita T; Tsukushi S; Iwata S; Nakamura T; Matsumine A; Yonemoto T; Nishida Y; Saita K; Kawai A; Matsumoto S; Yamaguchi T
Ann Surg Oncol; 2018 Apr; 25(4):912-919. PubMed ID: 29181683
[TBL] [Abstract][Full Text] [Related]
25. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
26. Nomogram for Individualized Prediction and Prognostic Factors for Survival in Patients with Primary Spinal Chordoma: A Population-Based Longitudinal Cohort Study.
Huang JF; Chen D; Sang CM; Zheng XQ; Lin JL; Lin Y; Ni WF; Wang XY; Li YM; Wu AM
World Neurosurg; 2019 Aug; 128():e603-e614. PubMed ID: 31054340
[TBL] [Abstract][Full Text] [Related]
27. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
28. Primary chordomas of the cervical spine: a consecutive series of 14 surgically managed cases.
Wang Y; Xiao J; Wu Z; Huang Q; Huang W; Zhu Q; Lin Z; Wang L
J Neurosurg Spine; 2012 Oct; 17(4):292-9. PubMed ID: 22920610
[TBL] [Abstract][Full Text] [Related]
29. Hand metastasis from a sacral chordoma.
Emori M; Kaya M; Sugita S; Soma T; Sasaki M; Yamashita T
Ann R Coll Surg Engl; 2014 Nov; 96(8):e8-11. PubMed ID: 25350167
[TBL] [Abstract][Full Text] [Related]
30. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma.
Uhl M; Welzel T; Jensen A; Ellerbrock M; Haberer T; Jäkel O; Herfarth K; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):597-603. PubMed ID: 25737378
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery.
Nishida Y; Kamada T; Imai R; Tsukushi S; Yamada Y; Sugiura H; Shido Y; Wasa J; Ishiguro N
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):110-6. PubMed ID: 20400242
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.
Bergh P; Kindblom LG; Gunterberg B; Remotti F; Ryd W; Meis-Kindblom JM
Cancer; 2000 May; 88(9):2122-34. PubMed ID: 10813725
[TBL] [Abstract][Full Text] [Related]
33. Sacral chordoma: 40-year experience at a major cancer center.
York JE; Kaczaraj A; Abi-Said D; Fuller GN; Skibber JM; Janjan NA; Gokaslan ZL
Neurosurgery; 1999 Jan; 44(1):74-9; discussion 79-80. PubMed ID: 9894966
[TBL] [Abstract][Full Text] [Related]
34. Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.
Handra-Luca A; Lesty C; Hammel P; Sauvanet A; Rebours V; Martin A; Fagard R; Fléjou JF; Faivre S; Bédossa P; Ruszniewski P; Couvelard A
Pancreas; 2012 Apr; 41(3):416-21. PubMed ID: 22158075
[TBL] [Abstract][Full Text] [Related]
35. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
[TBL] [Abstract][Full Text] [Related]
36. Oncologic and functional outcome following sacrectomy for sacral chordoma.
Hulen CA; Temple HT; Fox WP; Sama AA; Green BA; Eismont FJ
J Bone Joint Surg Am; 2006 Jul; 88(7):1532-9. PubMed ID: 16818979
[TBL] [Abstract][Full Text] [Related]
37. The surgical management of sacral chordomas.
Schwab JH; Healey JH; Rose P; Casas-Ganem J; Boland PJ
Spine (Phila Pa 1976); 2009 Nov; 34(24):2700-4. PubMed ID: 19910774
[TBL] [Abstract][Full Text] [Related]
38. Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control?
Fujiwara T; Tsuda Y; Stevenson J; Parry M; Jeys L
Int Orthop; 2020 Feb; 44(2):381-389. PubMed ID: 31863159
[TBL] [Abstract][Full Text] [Related]
39. A review of the surgical management of sacral chordoma.
Kayani B; Hanna SA; Sewell MD; Saifuddin A; Molloy S; Briggs TW
Eur J Surg Oncol; 2014 Nov; 40(11):1412-20. PubMed ID: 24793103
[TBL] [Abstract][Full Text] [Related]
40. Dedifferentiated chordoma arising in irradiated sacral chordoma.
Ikeda H; Honjo J; Sakurai H; Mitsuhashi N; Fukuda T; Niibe H
Radiat Med; 1997; 15(2):109-11. PubMed ID: 9192436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
